Anke Hensiek
University of Cambridge
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Anke Hensiek.
Neurology | 2005
R. H. S. R. Roxburgh; S Seaman; Thomas Masterman; Anke Hensiek; Stephen Sawcer; Sandra Vukusic; I. Achiti; Christian Confavreux; M. Coustans; E. le Page; G. Edan; Gavin McDonnell; Stanley Hawkins; Maria Trojano; Maria Liguori; Eleonora Cocco; M. G. Marrosu; F. Tesser; Marialucrez Leone; Alexandra Weber; Frauke Zipp; B. Miterski; Joerg T. Epplen; Annette Bang Oturai; P. S. Sørensen; Elisabeth G. Celius; N. T. Lara; Xavier Montalban; Pablo Villoslada; Ana Martins da Silva
Background: There is no consensus method for determining progression of disability in patients with multiple sclerosis (MS) when each patient has had only a single assessment in the course of the disease. Methods: Using data from two large longitudinal databases, the authors tested whether cross-sectional disability assessments are representative of disease severity as a whole. An algorithm, the Multiple Sclerosis Severity Score (MSSS), which relates scores on the Expanded Disability Status Scale (EDSS) to the distribution of disability in patients with comparable disease durations, was devised and then applied to a collection of 9,892 patients from 11 countries to create the Global MSSS. In order to compare different methods of detecting such effects the authors simulated the effects of a genetic factor on disability. Results: Cross-sectional EDSS measurements made after the first year were representative of overall disease severity. The MSSS was more powerful than the other methods the authors tested for detecting different rates of disease progression. Conclusion: The Multiple Sclerosis Severity Score (MSSS) is a powerful method for comparing disease progression using single assessment data. The Global MSSS can be used as a reference table for future disability comparisons. While useful for comparing groups of patients, disease fluctuation precludes its use as a predictor of future disability in an individual.
European Journal of Human Genetics | 2001
Francesca Coraddu; Stephen Sawcer; Sandra D'Alfonso; Marina Lai; Anke Hensiek; Elisabetta Solla; Simon Broadley; Cristina Mancosu; Maura Pugliatti; Maria Giovanna Marrosu; Alastair Compston
The prevalence of multiple sclerosis in Sardinia is significantly higher than in neighbouring Mediterranean countries, suggesting that the isolated growth of the population has concentrated genetic factors which increase susceptibility to the disease. The distinct HLA association of multiple sclerosis in Sardinia supports this interpretation. We have performed a whole genome screen for linkage in 49 Sardinian multiplex families using 327 markers. Non parametric linkage analysis of these data reveal suggestive linkage in the region of Chr 1q31, Chr 10q23 and Chr 11p15.
Genes and Immunity | 2001
Simon Broadley; Stephen Sawcer; Sandra D'Alfonso; Anke Hensiek; Francesca Coraddu; Julia Gray; R Roxburgh; David A. Clayton; C Buttinelli; Aldo Quattrone; Maria Trojano; Luca Massacesi; A. Compston
We have screened the whole genome for linkage in 40 Italian multiplex families with multiple sclerosis using 322 markers. The GENEHUNTER-PLUS program was used to analyse these data and revealed eight regions of potential linkage where the lod score exceeds the nominal 5% significance level (0.7). No region of linkage with genome-wide significance was identified and none of the markers showed evidence of statistically significant transmission disequilibrium. Overall these results have refined the linkage data relating to this disease in Italians modestly supporting some previously identified areas of interest and helping to exclude others.
Journal of Neurology | 2003
Anke Hensiek; R. Roxburgh; M. Meranian; S. Seaman; Taiwai Yeo; D Alastair S Compston; Stephen Sawcer
Abstract.Osteopontin transcription is increased in the central nervous system of patients with multiple sclerosis and rats with experimental allergic encephalomyelitis; where expression correlates with disease severity. We typed four single nucleotide polymorphisms located in exons 6 and 7 of the osteopontin gene in a large cohort of 1056 multiple sclerosis patients and 325 controls. We did not find significant allelic differences of the screened polymorphisms between the cases and controls and there was no allelic association with disease severity. Despite strong theoretical reasons to consider osteopontin as a potential candidate, the results of our study argue against the gene being a susceptibility locus for either the development or clinical severity of MS.
Journal of Neuroimmunology | 2006
Maria Ban; David R. Booth; Robert Heard; Graeme J. Stewart; An Goris; Koen Vandenbroeck; Bénédicte Dubois; Mikko Laaksonen; Jorma Ilonen; Mehdi Alizadeh; G. Edan; Marie Claude Babron; David Brassat; M. Clanet; Isabelle Cournu-Rebeix; Bertrand Fontaine; Gilbert Semana; Rene Goedde; Jörg T. Epplen; Alexandra Weber; Carmen Infante-Duarte; Frauke Zipp; Cecilia Rajda; Krisztina Bencsik; László Vécsei; Shirley Heggarty; Colin A. Graham; Stanley Hawkins; Maria Liguori; Patricia Momigliano-Richiardi
By combining all the data available from the Genetic Analysis of Multiple sclerosis in EuropeanS (GAMES) project, we have been able to identify 17 microsatellite markers showing consistent evidence for apparent association. As might be expected five of these markers map within the Major Histocompatibility Complex (MHC) and are in LD with HLA-DRB1. Individual genotyping of the 12 non-MHC markers confirmed association for three of them — D11S1986, D19S552 and D20S894. Association mapping across the candidate genes implicated by these markers in 937 UK trio families revealed modestly associated haplotypes in JAG1 (p=0.019) on chromosome 20p12.2 and POU2AF1 (p=0.003) on chromosome 11q23.1.
Journal of Neurology, Neurosurgery, and Psychiatry | 2003
Stephen Sawcer; Melanie Maranian; Anke Hensiek; R Roxburgh; Julia Gray; A. Compston
Autoimmune diseases, such as multiple sclerosis and Crohn’s disease, are believed to result from the effects of environmental agents acting on genetically susceptible individuals. Evidence from segregation analysis and systematic whole genome linkage studies indicates that the nature of this susceptibility is complex, involving several genes which each individually confer only modest excess risk. Recurrence risk analysis in the relatives of affected individuals1 together with the comparison of whole genome linkage studies across these diseases2 shows that there are likely to be both genes conferring an autoimmune diathesis in general and others determining precisely which autoimmune phenotype may result. On this basis it is reasonable to …
Journal of Neuroimmunology | 2003
Mefkure Eraksoy; Anke Hensiek; Murat Kürtüncü; Gulsen Akman-Demir; M. Kılınc; M. Gedizlioglu; B. Petek-Balcı; Ö. Anlar; C. Kutlu; Güher Saruhan-Direskeneli; H.A. İdrisoglu; E. Setakis; Alastair Compston; Stephen Sawcer
In order to screen the Turkish population for evidence of association with multiple sclerosis, we typed 6000 microsatellite markers in separately pooled DNA samples from 197 cases and 199 controls following the Genetic Analysis of Multiple sclerosis in EuropeanS (GAMES) protocol. Twelve markers showing evidence for association were identified. One of these markers lying directly in a region which is also implicated in the Turkish linkage screen (chromosome 5p15) and thus shows evidence for both linkage and association in independent data sets.
Journal of Neuroimmunology | 2003
Alexandra Weber; Carmen Infante-Duarte; Stephen Sawcer; Efrosini Setakis; Judith Bellmann-Strobl; Anke Hensiek; Sandra Rueckert; Constanze Schoenemann; Kjartan Benediktsson; Alastair Compston; Frauke Zipp
We report on a genome-wide screen for association with multiple sclerosis (MS) in the German population performed using 6000 microsatellite markers. These markers were typed in four DNA pools consisting of 234 MS patients (cases), 209 unrelated controls, 68 index patients from trio families and their 136 parents (related controls). Stringent analysis identified 11 markers showing apparent evidence for association. Five from regions previously identified in linkage studies and two from the MHC region on chromosome 6p21. These MHC markers are known to be in linkage disequilibrium with HLA class II alleles influencing susceptibility to MS. The identification of these markers serves as an important positive control.
Journal of Neuroimmunology | 2003
Eva Åkesson; Francesca Coraddu; Maria Giovanna Marrosu; Luca Massacesi; Anke Hensiek; Hanne F. Harbo; Annette Bang Oturai; Maria Trojano; Patricia Momigliano-Richiardi; Eleonora Cocco; Raffaele Murru; Jan Hillert; Alastair Compston; Stephen Sawcer
Genome-wide screens for linkage in multiplex families with multiple sclerosis (MS) from United Kingdom, Sardinia, Italy and the Nordic countries (Denmark, Finland, Norway and Sweden) have each shown suggestive or potential linkage on chromosome 10. The partially overlapping regions identified by these studies encompass around 60 cM of the chromosome. In order to explore this region further, we typed 13 microsatellite markers in the same 449 families originally studied in the individual screens. This additional genotyping increased the information extraction in the region from 52% to 79% and revealed increased support for linkage (MLS 2.5) peaking at 10p15.
Brain Research Bulletin | 2003
Anke Hensiek; Stephen Sawcer; D.A.S. Compston
Recent years have witnessed considerable advances in our understanding of monogenic neurodegenerative diseases, such as hereditary motor sensory neuropathy and Huntingtons Chorea. Progress has been slower in the genetic dissection of other more common neurological diseases with a complex mode of inheritance. The identification of relevant genes in some, such as Alzheimers disease (AD) or Parkinsons disease (PD), has been facilitated by characteristic pathological findings and autosomal dominant inheritance in a proportion of early onset families. Attempts to identify relevant genes for multiple sclerosis have highlighted the role of the major histocompatibility complex, but so far failed to unequivocally implicate other immunologic or structural candidate genes. Six linkage-based whole genome screens have been completed in multiple sclerosis and several regions of interest have been identified. As technology and progress in the human genome project advance, it has become clear that future studies of common neurological diseases will depend critically on the availability of large sample sizes and will have to address issues of disease heterogeneity.